1. Articles in category: Drug Resistance

    1-14 of 14
    1. SAHA sensitizes neuroblastoma to paclitaxel by inhibiting TRP14-mediated autophagy.

      SAHA sensitizes neuroblastoma to paclitaxel by inhibiting TRP14-mediated autophagy.

      Cancer Sci. 2017 May 12;:

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Abstract Paclitaxel is not as effective for neuroblastoma as most of the front-line chemotherapeutics due to drug resistance. This study explored the regulatory mechanism of paclitaxel-associated autophagy and potential solutions to paclitaxel resistance in neuroblastoma.

      Read Full Article
    2. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Elife. 2017 Apr 20;6:

      Authors: Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F

      Read Full Article
      Mentions: ALK MYCN
    3. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      Oncotarget. 2017 Mar 15;:

      Authors: Yang C, Tan J, Zhu J, Wang S, Wei G

      Abstract The transcriptional co-activator Yes-associated protein (YAP) is essential for Hippo pathway-driven tumorigenesis in various cancers. However, the expression and function of YAP in neuroblastoma remains elusive. Here, we show that YAP was highly expressed in Neuroblastoma (NB) and expression levels correlated with advanced tumor staging.

      Read Full Article
    4. Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.

      Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.

      Eur J Med Chem. 2017 Feb 27;130:336-345

      Authors: Lelle M, Freidel C, Kaloyanova S, Tabujew I, Schramm A, Musheev M, Niehrs C, Müllen K, Peneva K

      Read Full Article
    5. NDRG1 promotes the multidrug resistance of neuroblastoma cells with upregulated expression of drug resistant proteins.

      NDRG1 promotes the multidrug resistance of neuroblastoma cells with upregulated expression of drug resistant proteins.

      Biomed Pharmacother. 2015 Dec;76:46-51

      Authors: Zhang D, Jia J, Zhao G, Yue M, Yang H, Wang J

      Abstract BACKGROUND: Resistance to chemotherapeutic drugs and recurrence are two major causes of poor prognosis in many tumors including neuroblastoma.

      Read Full Article
    6. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.

      PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.

      Cancer Cell Int. 2015;15:91

      Authors: Qi L, Toyoda H, Xu DQ, Zhou Y, Sakurai N, Amano K, Kihira K, Hori H, Azuma E, Komada Y

      Abstract PURPOSE: AKT plays a pivotal role in the signal transduction of cancer cells. MK2206, an AKT inhibitor, has been shown to be an effective anti-cancer drug to a variety of cancer cell lines.

      Read Full Article
    7. High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance.

      High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance.

      Oncol Rep. 2015 Sep 16;

      Authors: Wang L, Zhang H, Sun M, Yin Z, Qian J

      Abstract Neuroblastoma (NB) is one of the most common tumors in childhood. Unfortunately, the survival outcomes remain unsatisfactory since NB commonly develops multidrug resistance.

      Read Full Article
    8. Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.

      Neuroblastoma is the most common cancer in infants and the fourth most common cancer in children. Aggressive cell growth and chemoresistance are notorious obstacles in neuroblastoma therapy. Exposure to the anticancer drug ellipticine inhibits efficiently growth of neuroblastoma cells and induces apoptosis in these cells. However, ellipticine induced resistance in these cells.

      Read Full Article
    9. CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.

      1Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, U.S.A. 2Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, U.S.A. zage@bcm.edu. Melanoma tumor cell sub-populations expressing a variety of specific molecular markers have been identified.

      Read Full Article
      Mentions: Chemotherapy G-CSF
    10. Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.

      1Paediatric Solid Tumour Biology and Therapeutics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. 2Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. 3Paediatric Solid Tumour Biology and Therapeutics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Louis.Chesler@icr.ac.uk.

      Read Full Article
      Mentions: ALK
    11. Resistance to the atypical retinoid ST1926 in SK-N-AS cells selected the subline rAS-ST with enhanced sensitivity to ATRA mediated by not conventional mechanisms: DNA damage, G2 accumulation and late telomerase inhibition.

      1Division of Paediatric Oncology, Catholic University of Rome, Rome, Italy. Electronic address: angeladifrancesco@tin.it. 2Division of Paediatric Oncology, Catholic University of Rome, Rome, Italy. 3Department of Systems Medicine, Section of Pharmacology, University of Rome "Tor Vergata", Italy. 4Department of Pharmacy and Biotechnology, University of Bologna, Bologna;Italy. 5Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

      Read Full Article
    1-14 of 14
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles